Infectious Disease · Medical Literature
Genotypic analysis of Plasmodium falciparum malaria parasites in a clinical trial of RTS,S vaccination in combination with seasonal malaria chemoprevention.
Abstract
Both vaccination and seasonal chemoprevention are effective interventions against malaria, but both morbidity and mortality due to malaria remain high, particularly in sub-Saharan Africa. A recent clinical trial showed that the combination of these interventions provided substantial protection against malaria over a five-year period. We performed amplicon-based genotyping of highly polymorphic parasite antigens within 1530 samples from this clinical trial. We evaluated the complexity of infection within these samples, finding that participants who received both interventions had less complex infections (fewer genetically distinct parasite strains) than participants who received either intervention given alone. We also evaluated the prevalence of parasites matching the vaccine construct CSP, at the level of haplotypes, epitopes, and individual amino acid changes. We found no significant differences in the prevalence of vaccine-matching alleles between vaccinated and unvaccinated groups. For context, this study genotyped about half as many non-vaccinated participants as the original phase 3 trial for RTS,S. While a comparable number of vaccinated individuals were genotyped in both studies, the infections in this study had less complex infections, leading to an overall lower number of parasite strains to analyze. These results suggest that the combination of vaccination with seasonal chemoprevention provides protection from infection, in addition to clinical disease, and they highlight the importance of continued molecular surveillance as malaria interventions are deployed.
Clinical relevance
Among children in sub-Saharan Africa enrolled in a clinical trial of RTS,S vaccination combined with seasonal malaria chemoprevention (SMC), does combined intervention reduce the complexity of circulating Plasmodium falciparum infections compared with either intervention alone, and does RTS,S vaccination lead to selection for vaccine-matching circumsporozoite protein (CSP) alleles in the parasite population? __SNAPSHOT__ {"studyDesign":"Secondary genotypic analysis of archived clinical trial samples from a double-blind, individually randomized, placebo-controlled, phase 3 trial (NCT03143218)","setting":"Mali (Bougouni district) and Burkina Faso (Houndé district); district hospitals and community health centers in highly seasonal malaria transmission areas of the Sahel","sampleSize":"n=1,530 samples genotyped from the parent trial (total parent trial enrollment: 5,920 children); exact per-arm genotyping denominators not reported in the abstract","population":"Children aged 5–17 months at enrollment with Plasmodium falciparum malaria in highly seasonal transmission settings in Mali and Burkina Faso; enrolled April 2017","intervention":"Seasonal RTS,S/AS01E vaccination (three priming doses prior to transmission season plus annual booster doses for up to five seasons) with or without seasonal malaria chemoprevention (SMC) with sulfadoxine–pyrimethamine plus amodiaquine (SP+AQ), administered at four to five monthly cycles per peak transmission season","comparator":"Three active comparator arms in parent trial: RTS,S/AS01E alone, SMC alone (with control vaccine: rabies or hepatitis A), and combined RTS,S/AS01E + SMC; genotypic analysis nested within this four-arm design","primaryOutcome":"For this genotypic sub-study: (1) complexity of infection (COI; number of genetically distinct parasite strains per sample) across intervention groups; (2) prevalence of vaccine-matching CSP alleles (assessed at the haplotype, epitope, and individual amino acid levels) between vaccinated and unvaccinated participants","followUp":"Five years (corresponding to the extended parent trial follow-up through 2021; exact follow-up duration for genotyped samples not separately reported in the abstract)","fundingSource":"Not reported in the abstract; the parent trial (Chandramohan et al., NEJM 2021; Dicko et al., Lancet Infect Dis 2024) received support from the Wellcome Trust, MRC, LSHTM, PATH, and GSK; funding source for this genotypic analysis not separately stated"}
Key findings
Across 1,530 genotyped samples, participants who received both RTS,S/AS01E vaccination and SMC demonstrated lower complexity of infection (fewer co-circulating genetically distinct parasite strains) compared with participants receiving either intervention alone. Specific COI values and between-group effect sizes (mean differences, confidence intervals, p-values) are not reported in the available abstract. For the second primary question—whether vaccination selected for vaccine-matching CSP alleles—no significant differences in the prevalence of vaccine-matching alleles were detected between vaccinated and unvaccinated groups, analyzed at the level of full CSP C-terminal haplotypes, defined epitope regions (Th2R/Th3R), and individual polymorphic amino acid positions. Sample size context: this study genotyped approximately half as many unvaccinated participants as the original RTS,S phase 3 genotypic analysis (Neafsey et al., NEJM 2015), which itself demonstrated allele-specific vaccine efficacy of 50.3% (95% CI 34.6–62.3) versus 33.4% (95% CI 29.3–37.2) for matched versus mismatched CSP parasites. In the current study, infections in both vaccinated and unvaccinated participants had lower overall complexity than in the original phase 3 trial, reducing the total number of parasite strains available for allele-specific analysis. No adverse events are reported as this was a genotypic sub-study. No NNT/NNH calculations are possible from the reported data.
Practice implications
This study established that combined RTS,S/AS01E vaccination plus SMC is associated with reduced complexity of P. falciparum infections—a biologically meaningful signal consistent with protection extending beyond prevention of clinical illness to suppression of multi-strain parasite acquisition. This is mechanistically plausible and aligns with the parent trial's demonstration of superior combined-intervention efficacy. The study did not establish evidence of immune selection pressure favoring vaccine-mismatched CSP strains in vaccinated children over up to five years of seasonal vaccination—an important reassurance against early vaccine-escape concerns in this Sahelian cohort. However, the study was underpowered relative to the original phase 3 genotypic analysis: approximately half the number of unvaccinated comparators were genotyped, and lower baseline COI reduced the overall number of analyzable parasite strains, limiting statistical power to detect modest allele frequency shifts. The findings apply to children aged 5–17 months in highly seasonal transmission settings in West Africa (Sahel/sub-Sahel); they cannot be directly extrapolated to perennial transmission regions, older children, or populations where seasonal RTS,S delivery is not co-administered with SP+AQ-based SMC. Critically, only an abstract is available for full review; reported statistical outputs (exact p-values, effect sizes, confidence intervals) for most comparisons are absent, and all findings should be considered preliminary pending full manuscript peer review and publication. __LIMITATIONS__ Only the abstract is available for full critical appraisal; key statistical outputs including exact COI between-group differences, confidence intervals, and p-values for most comparisons are not reported.,Genotyped sample size (~1,530 samples) is substantially smaller than the original phase 3 genotypic analysis for detecting allele-specific selection, with approximately half as many unvaccinated participants, reducing power to detect modest shifts in CSP allele frequency.,Lower baseline complexity of infection in this cohort (likely reflecting the combined intervention effect itself) further reduced the number of analyzable parasite strains, compounding statistical power limitations for allele-specific analyses.,This is a secondary analysis of a randomized trial; sampling of specimens for genotyping may not have been random or pre-specified with respect to all genotypic sub-questions, potentially introducing selection bias in which infections were characterized.,Generalizability is restricted to highly seasonal transmission settings (Mali, Burkina Faso, Sahel/sub-Sahel); results may not reflect parasite population dynamics or CSP allele frequencies in perennial or moderate-intensity transmission zones.,Five years of follow-up may be insufficient to detect late-emerging allele-frequency shifts driven by sustained vaccine-selective pressure, particularly given the lower-than-expected number of analyzable strains.,Funding source and potential conflicts of interest for this genotypic sub-study are not declared in the abstract, warranting review of the full publication's disclosure statements.,The study is set in two geographically proximate West African sites; CSP allele diversity may differ in other endemic regions, limiting generalizability of the null allele-selection finding. __BOTTOM_LINE_CATEGORY__ potentially_practice_informing __BOTTOM_LINE__ In children receiving RTS,S/AS01E vaccination combined with seasonal malaria chemoprevention over up to five years in Mali and Burkina Faso, combined intervention was associated with lower complexity of P. falciparum infections compared with either intervention alone, suggesting protection extends to the level of parasite strain acquisition. No evidence of vaccine-driven selection for mismatched CSP alleles was detected in vaccinated versus unvaccinated children, providing early reassurance against vaccine-escape pressure in this population, though the study was underpowered for definitive allele-frequency surveillance and only the abstract is currently available. These findings support the continued co-deployment of RTS,S with SMC in seasonal settings and underscore the importance of ongoing molecular surveillance as malaria vaccination scales up.